Bone in CKD Alkali Response (BICARb Pilot Trial)

The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength. * To evaluate mechanism(s) underlying the effects of potassium citrate on skeletal health. Participants will be asked to: * provide blood, urine and answer questions about health and diet three times during an 8 months period * undergo advanced bone imaging with high resolution-peripheral quantitative CT scan twice during 8 months * take study pills for 4-6 weeks at the beginning of the study to ensure safety * take either potassium citrate or placebo for 6 months during the blinded portion of the study As part of the study, there will be a run-in period followed by the placebo-controlled randomized clinical trial. Researchers will compare the bone imaging between the potassium citrate and the placebo groups at the end of the study.

NCT Number	NCT05918029
Lead Sponsor	Albert Einstein College of Medicine Collaborators: Columbia University, University of Pittsburgh Medical Center, University of Utah, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NYU Langone Health, Washington University School of Medicine
Conditions	Chronic Kidney Diseases, Bone Loss
Enrollment	6 participants
Start Date	2024-08-15
Primary Completion	2025-05-16 (estimated)
Study Completion	2025-05-16 (estimated)
Updated on ClinicalTrials.gov	2026-07-28